Search

Your search keyword '"Pack, Svetlana D."' showing total 240 results

Search Constraints

Start Over You searched for: Author "Pack, Svetlana D." Remove constraint Author: "Pack, Svetlana D."
240 results on '"Pack, Svetlana D."'

Search Results

1. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.

2. Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis

3. Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma

4. Publisher Correction: Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma

6. BORIS, A Novel Male Germ-Line-Specific Protein Associated with Epigenetic Reprogramming Events, Shares the Same 11-Zinc-Finger Domain with CTCF, The Insulator Protein Involved in Reading Imprinting Marks in the Soma

14. Supplementary Table 1 from Simultaneous Suppression of Epidermal Growth Factor Receptor and c-erbB-2 Reverses Aneuploidy and Malignant Phenotype of a Human Ovarian Carcinoma Cell Line

15. Supplementary Figure 2 from Conditional Expression of the CTCF-Paralogous Transcriptional Factor BORIS in Normal Cells Results in Demethylation and Derepression of MAGE-A1 and Reactivation of Other Cancer-Testis Genes

16. Supplementary Table 2 from Simultaneous Suppression of Epidermal Growth Factor Receptor and c-erbB-2 Reverses Aneuploidy and Malignant Phenotype of a Human Ovarian Carcinoma Cell Line

17. Supplementary Table 1 and Figure Legends from Conditional Expression of the CTCF-Paralogous Transcriptional Factor BORIS in Normal Cells Results in Demethylation and Derepression of MAGE-A1 and Reactivation of Other Cancer-Testis Genes

18. Supplementary Figures 1 and 3 from Conditional Expression of the CTCF-Paralogous Transcriptional Factor BORIS in Normal Cells Results in Demethylation and Derepression of MAGE-A1 and Reactivation of Other Cancer-Testis Genes

24. Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy

26. Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma

30. Additional file 10 of High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma

31. Additional file 8 of High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma

32. Additional file 6 of High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma

33. Additional file 5 of High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma

34. Additional file 7 of High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma

35. Additional file 4 of High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma

38. Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma.

47. Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series

49. Melanoma in patients with GATA2 deficiency

50. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma

Catalog

Books, media, physical & digital resources